Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SCOL.ST
- Price
- 0.01
- Stock movement up
- +0.00 (6.25%)
- Company name
- Scandion Oncology A/S
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.79M
- Ent value
- -7.33M
- Price/Sales
- -
- Price/Book
- 0.12
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 3.82%
- 1 year return
- -99.56%
- 3 year return
- -90.76%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-15
DIVIDENDS
SCOL.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.12 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 234.76M |
| EPS (TTM) | -0.21 |
| FCF per share (TTM) | -0.24 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -38.31M |
| Net income (TTM) | -32.47M |
| EPS (TTM) | -0.21 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 14.81M |
| Net receivables | 0.00 |
| Total current assets | 22.58M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 28.39M |
| Accounts payable | 2.53M |
| Short/Current long term debt | 164.00K |
| Total current liabilities | 4.69M |
| Total liabilities | 4.69M |
| Shareholder's equity | 23.70M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -35.72M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -35.72M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -137.01% |
| Return on Assets | -114.39% |
| Return on Invested Capital | -136.07% |
| Cash Return on Invested Capital | -149.67% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.01 |
| Daily high | 0.01 |
| Daily low | 0.01 |
| Daily Volume | 1.64M |
| All-time high | 22.90 |
| 1y analyst estimate | 0.26 |
| Beta | 1.28 |
| EPS (TTM) | -0.21 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 20 May 2025 |
Downside potential
Loading...
Downside potential data
| SCOL.ST | S&P500 | |
| Current price drop from All-time high | -99.95% | -12.04% |
| Highest price drop | -99.97% | -56.47% |
| Date of highest drop | 31 Mar 2025 | 9 Mar 2009 |
| Avg drop from high | -69.88% | -11.07% |
| Avg time to new high | 133 days | 12 days |
| Max time to new high | 999 days | 1805 days |
COMPANY DETAILS
Marketcap
2.79M
Marketcap category
Small-cap
Description
Scandion Oncology A/S, a clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase II clinical trial for the treatment of colorectal cancer; and in Phase I clinical trial for treating pancreatic cancer, as well as in preclinical studies for other cancer indications. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.
Employees
4
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found